Phage therapy as an alternative to antibiotics | World AMR Awareness Week 2026

Urinary Tract Infections (UTIs) affect over 400 million people globally each year and are among the most common bacterial infections. The infection recurs in 30-50% of patients, who can get stuck in a cycle of repeated antibiotic use that drives antimicrobial resistance (AMR).

As part of the REPhRAME project, researchers are developing new strategies for recurrent urinary tract infections that could limit AMR. They will evaluate the clinical efficacy and safety of phage therapy to explore its potential in addressing the clinical and socio-economic burden on patients and healthcare systems, particularly affecting women.

In a clinical trial carried out in several European countries, a phage cocktail will be used against E. coli, the pathogen that most frequently causes recurrent urinary tract infections. The trial will also test a new therapeutic approach that combines phage therapy with Fecal Microbiota Transfer, aiming to restore the host's microbial resilience and reduce the frequency of infection recurrence.


In an interview for World Antimicrobial Resistance Awareness Week, scientific coordinator Maria Vehreschild explains the role of phage therapy in combatting AMR and reflects on potential benefits for patients experiencing recurrent UTIs:

Next
Next

REPhRAME partners at the centre of major bacteriophage therapy developments